Table 3.
Comparisons of complications and safety outcomes between the minimally interrupted and uninterrupted groups
| Minimally interrupted | Uninterrupted | ||||
|---|---|---|---|---|---|
| n = 307 | DOAC | n = 277 | DOAC | P value | |
| Complications | |||||
| Thromboembolic complications | |||||
| Stroke/TIA | 0 | 0 | 1.000 | ||
| Deep venous thrombosis | 0 | 0 | 1.000 | ||
| Pulmonary embolism | 0 | 0 | 1.000 | ||
| Bleeding complications | |||||
| Major bleeding complications | |||||
| Periprocedural cardiac tamponade | 1 (0.3%) | Dabi | 0 | 1.000 | |
| Late cardiac tamponade | 1 (0.3%) | Riva | 0 | 1.000 | |
| Retroperitoneal bleeding | 0 | 0 | 1.000 | ||
| Decreased hemoglobin, >4 g/dL | 0 | 0 | 1.000 | ||
| Blood transfusion required | 0 | 0 | 1.000 | ||
| Minor bleeding complications | |||||
| Cardiac effusion | 0 | 0 | 1.000 | ||
| Groin hematoma | 8 (2.6%) | Api, 2: Dabi, 1: Edo, 2: Riva, 3 | 6 (2.2%) | Api, 2: Edo, 1: Riva, 3 | .729 |
| Nasal bleeding | 1 (0.3%) | Riva | |||
| Hematuria | 0 | 0 | 1.000 | ||
| Overall bleeding | 11 (3.6%) | 6 (2.2%) | .309 | ||
| Other | |||||
| Gastroparesis | 3 (1.0%) | Api,1: Edo,1: Riva, 1 | 0 | .285 | |
| Prolonged hospitalization | 0 | 0 | 1.000 | ||
| Safety outcome | |||||
| 14 (4.6%) | 6 (2.2%) | .112 | |||
Abbreviations: Api, apixaban; Dabi, dabigatran; DOAC, direct oral anticoagulants; Edo, edoxaban; P, probability value; Riva, rivaroxaban; TIA, transient ischemic attack.